Literature DB >> 921888

Tumour volume response, initial cell kill and cellular repopulation in B16 melanoma treated with cyclophosphamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea.

T C Stephens, J H Peacock.   

Abstract

The relationship between tumour volume response and cell kill in B16 melanoma following treatment in vivo with cyclophosphamide (CY) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) was investigated. Tumour volume response, expressed as growth delay, was estimated from measurements of tumour dimensions. Depression of in vitro colony-forming ability of cells from treated tumours was used as the measure of tumour cell kill. The relationship between these parameters was clearly different for the two agents studied. CY produced more growth delay (7.5 days) per decade of tumour cell kill than CCNU (2 to 3.5 days). The possibility that this was due to a technical artefact was rejected in favour of an alternative explanation that different rates of cellular repopulation in tumours treated with CY and CCNU might be responsible. Cellular repopulation was measured directly, by performing cell-survival assays at various times after treatment with doses of CY and CCNU which produced about 3 decades of cell kill. The rate of repopulation by clonogenic cells was much slower after treatment with CY than with CCNU, and this appears to account for the longer duration of the growth delay obtained with CY.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 921888      PMCID: PMC2025422          DOI: 10.1038/bjc.1977.195

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Differential sensitivity of colony-forming cells of hemopoietic tissue, Lewis lung carcinoma, and B16 melanoma to three nitrosoureas.

Authors:  N M Blackett; V D Courtenay; S M Mayer
Journal:  Cancer Chemother Rep       Date:  1975 Sep-Oct

2.  The response of hypoxic B16 melanoma cells to in vivo treatment with chemotherapeutic agents.

Authors:  R P Hill; J A Stanley
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701

3.  Estimation of tumor cell kill from Gompertz growth curves.

Authors:  H H Lloyd
Journal:  Cancer Chemother Rep       Date:  1975 Mar-Apr

4.  A comparison of the effects of radiation on tumour growth delay and cell survival. The effect of radiation quality.

Authors:  N J McNally
Journal:  Br J Radiol       Date:  1975-02       Impact factor: 3.039

5.  Plaque formation and isolation of pure lines with poliomyelitis viruses.

Authors:  R DULBECCO; M VOGT
Journal:  J Exp Med       Date:  1954-02       Impact factor: 14.307

6.  The effect of an hypoxic cell sensitizer on tumour growth delay and cell survival. Implications for cell survival in situ and in vitro.

Authors:  N J McNally
Journal:  Br J Cancer       Date:  1975-11       Impact factor: 7.640

7.  Cell survival in B16 melanoma after treatment with combinations of cytotoxic agents: lack of potentiation.

Authors:  T C Stephens; J H Peacock; G G Steel
Journal:  Br J Cancer       Date:  1977-07       Impact factor: 7.640

8.  Analysis of the cell population kinetics of transplanted tumours of widely-differing growth rate.

Authors:  G G Steel; K Adams; J C Barrett
Journal:  Br J Cancer       Date:  1966-12       Impact factor: 7.640

9.  A soft agar colony assay for Lewis lung tumour and B16 melanoma taken directly from the mouse.

Authors:  V D Courtenay
Journal:  Br J Cancer       Date:  1976-07       Impact factor: 7.640

10.  Sensitivity to cytotoxic agents of the EMT6 tumour in vivo: tumour volume versus in vitro plating. 1. Cyclophosphamide.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1977-02       Impact factor: 7.640

View more
  26 in total

Review 1.  The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome.

Authors:  Andrew D Redfern; Lisa J Spalding; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2018-06-08       Impact factor: 5.150

2.  Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.

Authors:  Edgar Ben-Josef; Jennifer Moughan; Jaffer A Ajani; Marshall Flam; Leonard Gunderson; JonDavid Pollock; Robert Myerson; Rani Anne; Seth A Rosenthal; Christopher Willett
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

3.  Growth response of B16 melanoma to in vivo treatment with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) at the initial stage after tumor transplantation.

Authors:  X H Li; G Paulus; G Atassi; N Buyssens
Journal:  Am J Pathol       Date:  1984-06       Impact factor: 4.307

Review 4.  Experimental chemotherapy studies: intercomparison of assays.

Authors:  P R Twentyman
Journal:  Br J Cancer Suppl       Date:  1980-04

Review 5.  Can dose-survival parameters be deduced from in situ assays?

Authors:  T E Wheldon
Journal:  Br J Cancer Suppl       Date:  1980-04

Review 6.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Authors:  Yuval Shaked
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

7.  Comparison of growth delay and cell survival as end-points of tumour response following treatment with combinations of cytotoxic agents.

Authors:  T C Stephens; J H Peacock
Journal:  Br J Cancer Suppl       Date:  1980-04

8.  Role of vascular normalization in benefit from metronomic chemotherapy.

Authors:  Fotios Mpekris; James W Baish; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-07       Impact factor: 11.205

9.  Reversibility of apoptosis in cancer cells.

Authors:  H L Tang; K L Yuen; H M Tang; M C Fung
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

10.  The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.

Authors:  Krupa J Patel; Ian F Tannock
Journal:  BMC Cancer       Date:  2009-10-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.